Walleye Capital LLC Incyte Corp Call Options Transaction History

Walleye Capital LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$57.33 - $68.61 $481,572 - $576,324	8,400 Added 200.0%	12,600 $832,000
Q2 2024 Aug 14, 2024	SELL	$51.18 - $63.75 $834,234 - $1.04 Million	-16,300 Reduced 79.51%	4,200 $254,000
Q1 2024 May 15, 2024	SELL	$56.55 - $66.59 $175,305 - $206,429	-3,100 Reduced 13.14%	20,500 $1.17 Million
Q4 2023 Feb 14, 2024	BUY	$52.16 - $64.19 $1.23 Million - $1.51 Million	23,600 New	23,600 $1.48 Million
Q1 2023 May 15, 2023	BUY	$70.23 - $86.01 $77,253 - $94,611	1,100 New	1,100 $79,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $890,838 - $1.21 Million	-14,100 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$73.04 - $95.72 $2.37 Million - $3.1 Million	-32,400 Reduced 69.68%	14,100 $1.23 Million
Q3 2019 Nov 14, 2019	BUY	$72.82 - $86.52 $1.3 Million - $1.54 Million	17,800 Added 62.02%	46,500 $3.45 Million
Q2 2019 Aug 14, 2019	BUY	$73.52 - $88.7 $1.62 Million - $1.96 Million	22,100 Added 334.85%	28,700 $2.44 Million
Q1 2019 May 15, 2019	BUY	$63.56 - $88.17 $419,496 - $581,922	6,600 New	6,600 $568,000

642

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $15.8B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.